
Daxor Corp
NASDAQ:DXR

Daxor Corp
EPS (Diluted)
Daxor Corp
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Daxor Corp
NASDAQ:DXR
|
EPS (Diluted)
$0
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
![]() |
Becton Dickinson and Co
NYSE:BDX
|
EPS (Diluted)
$6
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
0%
|
|
![]() |
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
22%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
![]() |
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$7
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
19%
|
|
![]() |
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$7
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
18%
|
|
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$6
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
18%
|
Daxor Corp
Glance View
Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The Company’s investment objectives are capital preservation, maintaining returns on capital with a high degree of safety and generating income from dividends and option sales to help offset operating losses from the Company’s operating division. The firm intends to maintain a diversified securities portfolio comprised primarily of electric utility company common and preferred stocks. The firm seeks to maintain a minimum of 80% of its portfolio in equity securities of utility companies.

See Also
What is Daxor Corp's EPS (Diluted)?
EPS (Diluted)
0.1
USD
Based on the financial report for Dec 31, 2024, Daxor Corp's EPS (Diluted) amounts to 0.1 USD.
What is Daxor Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-55%
Over the last year, the EPS (Diluted) growth was 83%. The average annual EPS (Diluted) growth rates for Daxor Corp have been -55% over the past three years .